Clinical Trials Logo

Myopic Maculopathy clinical trials

View clinical trials related to Myopic Maculopathy.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03882606 Enrolling by invitation - Clinical trials for Age-Related Macular Degeneration

Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy

Start date: May 22, 2019
Phase: N/A
Study type: Interventional

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss. Reduced near visual acuity is still a major problem with all forms of AMD and myopic maculopathy. Various intraocular lenses for near vision (IOLs) or telescopic systems have been described but are not widely accepted and almost all solutions require phakic status of the eye and are implanted during cataract surgery. Therefore, these devices are not appropriated for pseudophakic AMD and myopic maculopathy patients. Scharioth Macula Lens (SML, Medicontur) is a magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient. The implant has a bifocal optic, with a central 1.5mm diameter optical zone equivalent to +10D add and a peripheral zone optically neutral. The implantation of the add-on SML can improve the near visual acuity of pseudophakic patients with AMD and myopic maculopathy without impairing their distance visual acuity. The principal objective is to compare the near visual acuity, the far visual acuity and the self-reported vision health status before and after the SML implantation.